



5th Swedish Medicinal Chemistry Symposium

22-23 April, 2026, Stockholm, Sweden

Program

Wednesday 22 April	
09.15 – 09.45	Registration
09.45 – 10.00	Opening remarks – House keeping Chair: Lena Ripa, AstraZeneca
10.00 – 10.30	AP3-Driven Discovery of ACR-2316, a Dual WEE1/PKMYT1 Inhibitor with Superior Single-Agent Activity Caroline Wigerup, Acrivon Therapeutics
10.30 – 11.00	DNA-Encoded Libraries as a Hit Discovery Tool: Insights from the SciLifeLab DDD platform Johan Wannberg, SciLifeLab
11.00 – 11.30	Phenotypic screening towards the next generation antivirals Mikael Elofsson, Umeå University
11.30 – 12.00	Discovery of an IRAK4 inhibitor in early clinical development for the treatment of COPD Ina Terstiege, AstraZeneca
12.00 – 13.30	Lunch & Networking Chair: Ulf Nilsson, Lund University
13.30 – 14.00	Challenging the importance of chameleonicity for oral absorption of PROTACs Jenny Viklund, AstraZeneca
14.00 – 14.30	Programmable Skeletal Editing for Rapid Construction of sp³-Rich Scaffolds Sebastian Clementson, Lund University
14.30 – 15.00	One ring to rule all hallmarks of cancer – Discovery of combined galectin-1 and -3 inhibitors Fredrik Zetterberg, Biozet
15.00 – 15.45	Coffee break – Poster session – Exhibition
15.45 – 16.15	Chemical switching: Giving new functions to DNA damage repair enzymes Alice Eddershaw, Karolinska Institutet
16.15 – 16.45	Synthesis of a duocarmycin like enzymatically activated prodrug Christoffer Bengtsson, SciLifeLab
16.45 – 17.15	Discovery of Pirepemat, for the Prevention of Falls in Parkinson's Disease, Using Phenotypic In Vivo Screening Henrik Gradén, Integrative Research Laboratories Sweden
17.15 – 18.15	Refreshments & Poster session & Exhibition
18.15 – 20.30	Casual dinner



5th Swedish Medicinal Chemistry Symposium

22-23 April, 2026, Stockholm, Sweden

Program

Thursday 23 April	
09.00 – 09.05	House keeping Chair: Anders Karlén, Uppsala University
09.05 – 10.00	The Swedish Pharmaceutical Society 2026 Medicinal Chemistry Award & Award lecture
10.00 – 10.45	Coffee break – Poster session – Exhibition
10.45 – 12.00	Short presentations selected from poster abstracts 15 minutes each
10.45	PROTAC-mediated degradation of OGG1 as a Therapeutic Strategy for Idiopathic Pulmonary Fibrosis, <i>Oryn Purewal-Sidhu</i> , Karolinska Institutet
11.00	Structure-guided design of small-molecule agonists for neurotensin receptors identifies nonopioid analgesics, <i>Duy Vo</i> , Uppsala University
11.15	Tunable Aromatic Sulfoxide and Sulfone Warheads Enable Traceless Labelling of BTK Cys481, <i>Hampus Nyström</i> , University of Gothenburg
11.30	Identifying Membrane Channel Modulators via DNA-Encoded Library Screening in Native-Like Salipro Nano-Membrane Particles, <i>Anne-Sophie Tournillon</i> , Salipro Biotech
11.45	Enhancing cellular uptake of fluorescent nucleoside analogues for labeling of cellular RNA, <i>Eliza Baranska</i> , Chalmers University of Technology
12.00 – 13.20	Lunch & Networking Chair: Katarina Färnegårdh, Xspray Pharma
13.20 – 13.50	Discovery and development of GRK2-biased b2-adrenergic receptor agonists for the treatment of metabolic disorders Benjamin Pelcman, Atrogi
13.50 – 14.20	Exploring new strategies for design of β-lactamase inhibitors Annette Bayer, The Arctic University of Norway Tromsø
14.20 – 14.40	Break
14.40 – 15.10	Targeted Protein Degradation Through Modification Strategies Jonas Malmström, Ofichem Uppsala
15.10 – 15.40	Discovery and Optimization of a Potent Bicyclic Peptide Molecule Inhibiting NPR3 for the Treatment of Chronic kidney diseases Anais Noisier, AstraZeneca
15.40 – 15.55	Poster award
15.55 – 16.00	Concluding remark – End of Meeting